ES2561163T3 - Arilamidas del ácido bifenil-4-il-sulfónico y su uso como agentes terapéuticos - Google Patents

Arilamidas del ácido bifenil-4-il-sulfónico y su uso como agentes terapéuticos Download PDF

Info

Publication number
ES2561163T3
ES2561163T3 ES08718826.4T ES08718826T ES2561163T3 ES 2561163 T3 ES2561163 T3 ES 2561163T3 ES 08718826 T ES08718826 T ES 08718826T ES 2561163 T3 ES2561163 T3 ES 2561163T3
Authority
ES
Spain
Prior art keywords
independently
ring
phenyl
ord1
exactly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08718826.4T
Other languages
English (en)
Spanish (es)
Inventor
Iain Robert Greig
Robert Jurgen Van't Hof
Stuart Hamilton Ralston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Original Assignee
University of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Aberdeen filed Critical University of Aberdeen
Application granted granted Critical
Publication of ES2561163T3 publication Critical patent/ES2561163T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES08718826.4T 2007-03-21 2008-03-20 Arilamidas del ácido bifenil-4-il-sulfónico y su uso como agentes terapéuticos Active ES2561163T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0705400 2007-03-21
GBGB0705400.0A GB0705400D0 (en) 2007-03-21 2007-03-21 Therapeutic compounds andm their use
PCT/GB2008/000989 WO2008114022A1 (en) 2007-03-21 2008-03-20 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
ES2561163T3 true ES2561163T3 (es) 2016-02-24

Family

ID=38024559

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08718826.4T Active ES2561163T3 (es) 2007-03-21 2008-03-20 Arilamidas del ácido bifenil-4-il-sulfónico y su uso como agentes terapéuticos

Country Status (11)

Country Link
US (1) US8524778B2 (OSRAM)
EP (1) EP2137141B1 (OSRAM)
JP (1) JP5450105B2 (OSRAM)
CA (1) CA2681320C (OSRAM)
DK (1) DK2137141T3 (OSRAM)
ES (1) ES2561163T3 (OSRAM)
GB (1) GB0705400D0 (OSRAM)
HR (1) HRP20160183T1 (OSRAM)
HU (1) HUE028656T2 (OSRAM)
SI (1) SI2137141T1 (OSRAM)
WO (1) WO2008114022A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
US9233946B2 (en) 2010-09-17 2016-01-12 Kancera Ab Sulfonamide compounds
US10941109B2 (en) 2011-06-13 2021-03-09 Ergon Pharmaceuticals Llc Compositions and methods of treatment using a BCAT1 inhibitor
WO2012173987A2 (en) 2011-06-13 2012-12-20 Ergon Pharmaceuticals Llc Methods of treatment using a bcat1 inhibitor
US9708276B2 (en) 2011-10-12 2017-07-18 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
EP2794009B1 (en) * 2011-12-22 2017-08-30 Kancera AB Bisarylsulfonamides useful in the treatment of inflammation and cancer
MX2015006844A (es) * 2012-12-10 2015-09-16 Hoffmann La Roche Derivados de bencilsulfonamida como moduladores del receptor huerfano relacionado al receptor de retinoide (rorc).
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
EP3046561B1 (en) 2013-09-20 2023-02-22 University of Pittsburgh - Of the Commonwealth System of Higher Education Compounds for treating prostate cancer
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
EP3262028B1 (en) 2014-12-17 2021-10-27 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
WO2018146129A1 (en) 2017-02-07 2018-08-16 Orthogenics As Biomarkers for diagnosing implant related risk of implant revision due to aseptic loosening
WO2020097408A1 (en) * 2018-11-09 2020-05-14 Nimbus Artemis, Inc. Acly inhibitors and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB597810A (en) 1943-04-12 1948-02-04 Gen Printing Ink Corp Improvements in or relating to derivatives of diphenyl
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB2001307A (en) * 1977-07-01 1979-01-31 American Cyanamid Co Sulphonamide blood complement inhibitors
US4119784A (en) * 1977-07-01 1978-10-10 American Cyanamid Company Anionic substituted sulfonamido biphenyls
DE3000519A1 (de) 1979-02-01 1980-08-14 Byk Gulden Lomberg Chem Fab Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel
DE3535167A1 (de) 1985-10-02 1987-04-09 Boehringer Mannheim Gmbh Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
AU1118097A (en) 1995-10-30 1997-05-22 Smithkline Beecham Corporation Protease inhibitors
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
AU2421797A (en) 1996-03-15 1997-10-01 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
PL331338A1 (en) 1996-07-22 1999-07-05 Monsanto Co Thiosulphonamidic metaloprotease inhibitors
AU731737B2 (en) 1996-10-16 2001-04-05 Wyeth Holdings Corporation The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU5362998A (en) 1996-11-27 1998-06-22 Du Pont Pharmaceuticals Company Novel integrin receptor antagonists
AU6780398A (en) 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
HUP0002951A3 (en) 1997-05-08 2002-10-28 Smithkline Beecham Corp Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
DE59802394D1 (de) 1997-05-09 2002-01-24 Hoechst Ag Substituierte Diaminocarbonsäuren
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
AP1269A (en) 1998-01-23 2004-04-03 Aventis Pharma Deutschland Gmbh Novel salfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion.
EP1053226A1 (en) 1998-02-04 2000-11-22 Novartis AG Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
JPH11246527A (ja) 1998-03-02 1999-09-14 Shionogi & Co Ltd Ｍｍｐ−８阻害剤
EP0960882A1 (en) 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
WO2001070720A2 (en) 2000-03-21 2001-09-27 The Procter & Gamble Company Carbocyclic side chain containing, n-substituted metalloprotease inhibitors
WO2001090077A1 (en) 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
AU2002228316A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
JPWO2002074298A1 (ja) 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
JP2004535390A (ja) * 2001-05-07 2004-11-25 スミスクライン・ビーチャム・コーポレイション スルホンアミド
NZ541950A (en) 2001-08-09 2007-02-23 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
GB0126157D0 (en) * 2001-10-31 2002-01-02 Univ Aberdeen Therapeutic compounds
AU2003221160A1 (en) 2002-03-27 2003-10-08 Shionogi And Co., Ltd. Decomposition inhibitor for extracellular matrix of cartilage
ATE469903T1 (de) 2002-09-04 2010-06-15 Schering Corp Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine
DE10251170A1 (de) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
DK1638544T3 (da) 2003-05-07 2008-03-31 Univ Aberdeen Ketoner og reducerede ketoner som terapeutiske midler til behandling af knogletilstande
JPWO2004106290A1 (ja) 2003-05-14 2006-07-20 キッセイ薬品工業株式会社 アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
EP1696915A1 (en) 2003-12-19 2006-09-06 Pfizer, Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
GB0405193D0 (en) * 2004-03-08 2004-04-21 Medical Res Council Compounds
EP1756025A1 (en) 2004-05-05 2007-02-28 Novo Nordisk A/S Sulfonamide derivatives
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
WO2005123089A2 (en) * 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
KR20080016649A (ko) 2005-06-16 2008-02-21 화이자 인코포레이티드 Ｎ-(피리딘-2-일)-술폰아미드 유도체
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
TW200720261A (en) * 2005-08-31 2007-06-01 Sankyo Co Phenylene derivatives
EP1984344B1 (en) 2005-12-29 2012-09-26 Lexicon Pharmaceuticals, Inc. Multicyclic amino acid derivatives and methods of their use
US7560597B2 (en) * 2007-03-08 2009-07-14 The University Court Of The University Of Aberdeen 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use

Also Published As

Publication number Publication date
JP2010522152A (ja) 2010-07-01
JP5450105B2 (ja) 2014-03-26
SI2137141T1 (sl) 2016-03-31
EP2137141A1 (en) 2009-12-30
CA2681320C (en) 2015-05-19
WO2008114022A1 (en) 2008-09-25
GB0705400D0 (en) 2007-05-02
CA2681320A1 (en) 2008-09-25
US8524778B2 (en) 2013-09-03
EP2137141B1 (en) 2015-12-02
HRP20160183T1 (hr) 2016-03-25
HUE028656T2 (en) 2016-12-28
US20100286266A1 (en) 2010-11-11
DK2137141T3 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
ES2561163T3 (es) Arilamidas del ácido bifenil-4-il-sulfónico y su uso como agentes terapéuticos
ES2544511T3 (es) Compuestos de aril-fenil-sulfonamido-cicloalquilo y su uso
ES2266227T3 (es) Nuevos compuestos de (tio)urea y composiciones farmaceuticas que los contienen.
ES2359564T3 (es) Derivados de benzamida útiles como inductores de diferenciación celular.
ES2334889T3 (es) Antagonistas de la hormona concentradora de melanina (mch) y su uso en el tratamiento de la obesidad.
ES2270475T3 (es) Nuevos antagonistas de receptores de integrina.
ES2353077T3 (es) Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos.
ES2875899T3 (es) Compuestos inhibidores de autotaxina
ES2228557T3 (es) Aminobenzofenonas con inhibidores de la il-1beta y tnf-alfa.
JP2003519676A (ja) 抗菌剤
KR20160009667A (ko) 염증의 예방 및 치료를 위한 크리오피린 억제제
ES2969242T3 (es) Acidos fenil y piridinil hidroxámicos
SK282155B6 (sk) Trisubstituované fenylové deriváty, spôsoby ich prípravy, ich použitie a farmaceutické prostriedky obsahujúce tieto deriváty
Clark et al. 2-(Substituted phenyl) oxazolo [4, 5-b] pyridines and 2-(substituted phenyl) oxazolo [5, 4-b] pyridines as nonacidic antiinflammatory agents
BR112015031527B1 (pt) N-(4-hidróxi-4-metil-ciclo-hexil)-4-fenil- benzenossulfonamidas e n-(4- hidróxi-4-metil-ciclo-hexil)-4-(2-piridil) benze-nossulfonamidas, seus usos, composição farmacêutica e seu método de preparação
AU2013307688A1 (en) Ddr2 inhibitors for the treatment of osteoarthritis
EA202191968A1 (ru) Новые замещенные производные сульфонилмочевины
KR20110053379A (ko) 아미노 치환 벤조일 유도체군, 그리고 이의 제조 및 용도
KR20140100476A (ko) 헤테로아릴 하이드록삼산 유도체 및 바이러스성 질환을 치료, 개선 또는 예방하는데 있어서의 이들의 용도
JPS63239259A (ja) 薬剤化合物
BRPI0616239A2 (pt) derivados de Ácido 4-amino-tieno[3,2-c]piridina-7-carboxÍlico, formulaÇço farmacÊutica contendo os mesmos bem como seus usos
PT87854B (pt) Processo para a preparacao de derivados de tio-ureia
ES2263058T3 (es) Derivados de pirimidina como inhibidores selectivos de cox-2.
ES2221107T3 (es) Cromanos sustituidos con sulfonamindas (bloqueadores del canal de k+), procedimiento para su preparacion, su utilizacion como medicamento, asi como preparados farmaceuticos que los contienen.
US20030162818A1 (en) Acylsulfonamide derivative